



TARGET
PharmaSolutions

NISS Virtual Industry Career Fair

Richard C. Zink, PhD
Senior Director, Data Management and Statistics
TARGET PharmaSolutions

rzink@targetpharmasolutions.com

My Background

- Education
 - BS in Mathematics (University of Maryland Baltimore County)
 - MS and PhD in Biostatistics (University of North Carolina at Chapel Hill)
- Work
 - Internship at National Institute on Aging at National Institutes of Health (government)
 - Research assistant and consultant at UNC (academia)
 - Bristol-Myers Squibb (large pharmaceutical company)
 - Inspire Pharmaceuticals (small biotech company)
 - JMP Life Sciences, SAS Institute (software company)
 - TARGET PharmaSolutions (data company)
- Other
 - Adjunct Assistant Professor of Biostatistics at UNC-Chapel Hill
 - Associate Editor for *Therapeutic Innovation and Regulatory Science*
 - Past-Chair, Biopharmaceutical Section of the ASA

Introduction



The Cost of Clinical Trials

- Clinical trials are expensive
 - Tufts Center for the Study of Drug Development
 - \$0.8 billion USD in 2000
 - \$2.6 billion USD in 2013
- If study costs continue to rise at the current pace, clinical trials to establish efficacy and tolerability will become impossible to conduct
- Making drugs unavailable for areas of unmet need
- Stifling innovation in established treatment areas
- Placing an extreme price burden on consumers and health care systems

Real-World Data (RWD)

- Utilize available data sources
 - Electronic health records
 - Claims data
 - Patient registries
 - Pharmacovigilance databases
- Answer questions of regulatory importance more quickly and cost-effectively for a larger body of patients than those seen in clinical trials
- Issues with data quality and structure, selection-bias
- Selection-bias managed through propensity weighting, matching, stratification


- 21 Century Cures Act (2016)
 - Support the approval of new indications for approved drugs
 - Support or satisfy post-approval study requirements
- Framework for FDA's Real World Evidence Program (2018)
 - RWD are data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources
 - RWE is the clinical evidence about the usage and potential benefits or risks of a medical product derived from RWD

Overview of TARGET PharmaSolutions®



TARGET creates turnkey real-world evidence communities that generate data and deliver insights

Organizes a community of key stakeholders around a specific disease



In Progress: COVID-19

Bridging the Gap Between RWE & RCT




The TARGET Difference

- ✓ **Strict academic oversight**
- ✓ **Protocols designed by disease experts**
- ✓ **FDA CRADA**
- ✓ **Evidence from real world practice**
- ✓ **Patient diversity**
- ✓ **Regulatory grade data quality/standards**
- ✓ **Matched biobank basic research**
- ✓ **Peer-reviewed publications**
- ✓ **Clinical practice guideline development**
- ✓ **Integration of multiple data sources**

Applications for TARGET's RWD

TARGET's RWD can be applied across the drug development and commercialization spectrum



Opportunities for Statisticians and Data Scientists



Unique Intersection(s)


- Industry, Regulatory, Academia
- Observational studies and RCTs
- Data from multiple sources
- A host of data and analytical challenges to appropriately analyze, interpret, and report data to address questions related to a particular disease

Primary Responsibilities


- Quarterly Reports
 - Provides an overall snapshot of study progress
 - Enables interactive visualization tool
- Publications
 - Abstracts to major conferences for posters and presentations
 - Manuscripts
- Confidential Queries
 - Asked by individual companies to answer a specific question of scientific interest
- Other
 - Data Linkage and de-identification

Query Example Overview


Natural History of Disease Analysis



Biospecimen-Related Analysis



Drug-Specific Analysis



- Statistics
 - Methods for observational data
 - Categorical and survival analysis
- Programming
 - Languages: SAS, R, Python
 - Data standards (e.g., CDISC)
- Soft skills
 - Technical writing
 - Public speaking
 - Presentation skills
 - Improvisation?
(See what the [New York Times](#), [PRI](#), [AAAS](#), and [Science Friday](#) have to say)

Wrapping Up



Final Thoughts

- A lot of opportunity at TARGET PharmaSolutions to engage intellectual and technical muscles
- Great deal of exposure to many facets of the medical product industry
- Greater understanding of patients who may not be well-represented in typical clinical development

Some Practical Advice

- Possible to switch between industries depending on how you conduct your career
 - Methodological research and teaching short courses makes it easier to switch to academia
 - Experience at the FDA makes you very attractive to pharmaceutical companies
 - CROs make it possible to achieve a diversity of experience quickly
- Jobs descriptions are written for the perfect candidate who often doesn't exist
- Update your curriculum vitae (CV) in real time, not when looking to find or switch jobs